JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
February 25, 2021
Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) LAS VEGAS, Feb. 25, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is has... READ MORE
JanOne Announces Closing of $6.0 Million Common Stock Offering
February 2, 2021
Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate LAS VEGAS, February XX, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering... READ MORE
JanOne Prices $6.0 Million Common Stock Offering
January 29, 2021
Las Vegas, NV, January 29, 2021 (GLOBE NEWSWIRE) -- JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 571,428 shares of its common... READ MORE
Dr. Giordano’s interview with eHealth Radio Network
December 15, 2020
Our CSO, Dr. Giordano, sat down with @EricDye to discuss JanOne, treating the #opioid industry, bringing to market drugs with non-addictive pain-relieving properties, and more. $JAN #Healthcare #Medical Listen to the full interview here via @eHealthRadio https://ehealthradio.podbean.com/e/janone-treating-the-opioid-industry-and-bringing-to-market-drugs-with-non-addictive-pain-relieving-properties READ MORE
September 24, 2020
Company continues to make progress on its potential treatment for PAD, a disease affecting 200 million people worldwide LAS VEGAS, NV Sept. 24, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that the Company has started production... READ MORE
September 22, 2020
Company pursuing additional application for JAN101 to treat COVID-19 complications Stable formulation and engineering for JAN101 will support Phase 2b PAD Study under the FDA’s Investigational New Drug (IND) #111703, expected to begin the first quarter of 2021 Scientific Advisory Board bolstered by expert additions LAS VEGAS, NV Sept. 23, 2020 – JanOne Inc. (Nasdaq:... READ MORE
JanOne Announces Strategic Plan to Divest its Legacy Businesses
September 16, 2020
Update on plans for sale of recycling business. Divesting will allow for focus on core life science assets LAS VEGAS, NV, Sept. 16, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, provided an update today regarding its initiatives to... READ MORE
September 3, 2020
Bottling and labeling partner Eurofins CDMO (Alphora Research, Inc.) to ensure JanOne clinical research maintains compliance with GMP and FDA regulations LAS VEGAS, NV Sept. 3, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, has confirmed stability of its... READ MORE
August 28, 2020
Partnership to ensure clinical compliance for active and placebo dosing for PAD phase 2b trials planned for early 2021 and potential trials for treating Covid-19 vascular complications LAS VEGAS, NV Aug. 28, 2020 – JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving... READ MORE